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SUMMARY 
 
Loss of functional cardiomyocytes is a major determinant of heart failure after myocardial 
infarction. Previous high throughput screening studies have identified a few microRNAs that 
can induce cardiomyocyte proliferation and stimulate cardiac regeneration in mice. Here we 
show that all the most effective of these microRNAs activate nuclear localization of the 
master transcriptional cofactor YAP and induce expression of YAP-responsive genes. In 
particular, miR-199a-3p directly targets two mRNAs coding for proteins impinging on the 
Hippo pathway, the upstream YAP inhibitory kinase TAOK1 and the E3 ubiquitin ligase 
TrCP, which leads to YAP degradation. Several of the pro-proliferative microRNAs 
(including miR-199a-3p) also inhibit filamentous actin depolymerization by targeting 
Cofilin2, a process that by itself activates YAP nuclear translocation. Thus, activation of YAP 
and modulation of the actin cytoskeleton are major components of the pro-proliferative action 
of miR-199a-3p and other miRNAs that induce cardiomyocyte proliferation. 
 
 
Keywords: Cardiomyocyte; cell cycle; Cofilin2; cytoskeleton; Hippo; microRNA; 
regeneration; YAP 
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INTRODUCTION 
 
Despite remarkable progresses made by surgical and medical therapies, the long-term survival 
of patients with heart disease remains poor. Cardiac injury, as a consequence of acute or 
chronic ischemia, hypertension or inflammation, typically results in the irreversible loss of 
cardiomyocytes (CMs), which are incapable of clinically significant regeneration in the adult 
life. Scarring and fibrosis thus represent a general hallmark of cardiac repair and aging, with 
consequent progressive loss of cardiac function (reviewed in refs.: (Laflamme and Murry, 
2011; Xin et al., 2013b; Zacchigna and Giacca, 2014)). 
Cardiac regeneration after damage, however, occurs in other species during the entire life 
(Bettencourt-Dias et al., 2003; Poss et al., 2002) and, in mammals, during the fetal and early 
post-natal periods (Porrello et al., 2011). Regeneration is sustained by the effective 
proliferation of already formed CMs, which only partially revert from their terminal 
differentiation state and re-enter the cell cycle, with no apparent involvement or stem or 
progenitor cell expansion (Eschenhagen et al., 2017). The reasons why, in mammals, this 
regenerative property is rapidly lost after birth are only partially understood, and might be 
consequent to DNA damage caused by reactive oxygen species or to postnatal increase in 
mechanical load, both of which occur after birth (Canseco et al., 2015; Nakada et al., 2017). 
Whatever the mechanisms, the manipulation of the genetic programs that control CM 
proliferation by exogenous, therapeutic interventions might represent an innovative manner to 
achieve cardiac regeneration in adulthood. 
In this context, increasing evidence indicates that CM proliferation in the embryonic and fetal 
life is under the control of the Hippo signal transduction pathway. In cardiac cells, the positive 
effector of this pathway is the transcriptional coactivator Yes-associated protein (YAP), 
which, in its de-phosphorylated form, localizes to nucleus and associates with the 
transcriptional enhanced associate domain (TEAD) 1-4 transcription factors to drive gene 
expression and stimulate cell proliferation. Deletion of floxed YAP alleles using Nkx2.5- or 
Tnnt2-drivers, which are expressed during early heart development, results in myocardial 
hypoplasia and early embryonic lethality (von Gise et al., 2012; Xin et al., 2011), while 
deletion of YAP at a later developmental stage leads to cardiac dilation and failure (Del Re et 
al., 2013; Xin et al., 2013a). On the contrary, transgenic overexpression of a constitutively 
active, nuclear YAP mutant causes CM hyper-proliferation (Xin et al., 2013a; Xin et al., 
2011).  
In resting CMs, YAP is maintained inactive in the cytoplasm by phosphorylation by a kinase 
cascade signaling. MST1/2 (Hippo in Drosophila, in which the pathway was originally 
discovered by genetic screens (Pan, 2010; Saucedo and Edgar, 2007)), in complex with 
SAV1, phosphorylates and activates LATS1/2, which associates with MOB1 and in turn 
phosphorylates and inactivates YAP. Genetic deletion of MST1, SAV1 and LATS determines 
cardiac hyperplasia  (Heallen et al., 2011), while overexpression of MST1 (Yamamoto et al., 
2003) or LATS2 (Matsui et al., 2008) leads to post-natal dilated cardiomyopathy, supporting 
the essential role of this pathway in the regulation of CM proliferation during embryonic and 
fetal development. Consistent with this notion, transgenic mice overexpressing activated YAP 
or lacking functional MST1 both repair myocardial injury through regeneration instead of 
fibrosis (Heallen et al., 2013; Xin et al., 2013a).  
Work from several laboratories in the last few years has shown that most biological functions 
of CMs, including cell proliferation, are controlled by the microRNA (miRNA) network 
(Giacca and Zacchigna, 2015; van Rooij, 2011). In particular, a previous whole-genome, 
synthetic miRNA screening revealed several human miRNA capable to induce significant 
proliferation of neonatal rat and mouse CMs (Eulalio et al., 2012). Among these miRNAs, 
there were miR-199a-3p, miR-590-3p, miR-1248, miR-1825 and two large families of 
miRNAs, the miR-17/92 and the miR-302/367 cluster, which previous work had shown to be 
essentially involved in the regulation of embryonic cell proliferation (Barroso-del Jesus et al., 
2009; Tiscornia and Izpisua Belmonte, 2010). Transgenic mouse experiments indicate that 
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both these clusters are involved in the regulation of cardiac cell proliferation during 
development, since their knock-out leads to cardiac hypoplasia while, conversely, their 
overexpression expands the CM pool during embryogenesis (Chen et al., 2013; Tian et al., 
2015). Of interest, at least two of the miRNAs that we identified, miR-199a-3p and miR-590-
3p, were capable to induce cardiac regeneration after myocardial infarction (MI), either when 
expressed using AAV vectors (Eulalio et al., 2012) or when delivered as naked miRNA 
mimics (Lesizza et al., 2017). Analogous findings were also achieved by systemic delivery of 
miR302b/c (Tian et al., 2015). 
The identification of multiple miRNAs capable of inducing CM proliferation raises the 
obvious question as whether they act through multiple or specific pathways, which are the 
individual mRNA targets that mediate their action and to what extent they impact on the 
molecular mechanisms known to regulate CM proliferation. The work described here is aimed 
at providing answers to these questions. 
 
RESULTS 
Activation of the YAP transcriptional coactivator mediates the function of miRNAs that 
induce cardiomyocyte proliferation 
We wanted to understand the mechanism of action of a series of human miRNAs that were 
previously shown to induce CM proliferation (Eulalio et al., 2012). These miRNAs included 
human miR-590-3p (the most effective in our original screening in rat cells), miR-199a-3p 
(the most effective in mouse cells), three members of the miR-302 family (miR-302d, miR-
302c and miR-373, known to be enriched in embryonic stem cells (Barroso-del Jesus et al., 
2009), miR-1825, miR-1248, miR-18a*, miR-33b* and miR-30e*. Figure S1 reports the 
human sequences of these miRNAs and their levels of conservation in mouse, rat and pig. 
First, we assessed the possible involvement of the Hippo pathway in mediating the effect of 
these miRNAs. We started by analyzing the extent of TEAD activation by transfecting 
neonatal rat CMs with a TEAD-responsive, luciferase reporter plasmid together with each of 
these pro-proliferative miRNAs (scheme in Figure 1A). Transfection of constitutively 
activated YAP (YAP5SA) served as a positive control. We found that the TEAD reporter 
activity was significantly increased upon treatment with all the investigated miRNAs (Figure 
1B). Next, we assessed the levels of cytoplasmic and nuclear (activated) YAP1 in miRNA-
treated CMs. In all cases, cell treatment with the pro-proliferative miRNAs correlated with 
increased levels of non-phosphorylated YAP1 in the nucleus (Figures 1C and 1D for a 
representative western blot and quantification, respectively). Thus, miRNA transfection 
correlates with increased YAP activity in the cells. 
We then wondered whether YAP activation was an essential requisite for the miRNAs to 
induce CM proliferation. To investigate this possibility, we knocked down YAP1 using a 
specific siRNA (knock down >85%; Figure 1E) and simultaneously treated CMs with the 10 
miRNAs under investigation, followed by analysis of 5-ethynyl-2´-deoxyuridine (EdU) 
incorporation as a surrogate marker for cell proliferation. We found that, in all cases, YAP 
knockdown prevented the pro-proliferative effect of all the investigated miRNAs (Figure 1F). 
Representative images of proliferating CM cultures in response to treatment with miR-199a-
3p and miR-590-3p and inhibition of their effect upon YAP downregulation are shown in 
Figure 1G. Our previous published results (Eulalio et al., 2012) and unpublished data indicate 
that all the analyzed 10 miRNAs, in addition to inducing DNA synthesis as measured by EdU 
incorporation, also stimulate cell passage through G2/M (H3-Ser10 phosphorylation; cf. also 
later Figure 5) and karyokinesis (Aurora B localization in midbodies). 
From these experiments, we conclude that increase in YAP nuclear activity is an essential 
requisite to mediate induction of CM proliferation by the 10 investigated miRNAs. 
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Identification of mRNA targets mediating miRNA-induced YAP activation 
We next investigated the mechanism by which the 10 proliferative miRNAs lead to YAP 
activation. First, we generated a catalogue of the genes known to participate, either directly or 
indirectly, in the regulation of YAP transactivation (203 genes); for each of these genes we 
annotated the bioinformatics prediction of miRNA targeting according to the TargetScan 
software (Table S1). Because of the large number of catalogued genes in the Hippo pathway, 
we performed a total RNA sequencing (RNA-seq) analysis to narrow down the list of 
candidates to a smaller set of genes. To this effect, we transfected neonatal rat CMs with 6 of 
the investigated miRNAs (miR-590-3p, miR-199a-3p, miR-1825, miR-302d, miR-373 and 
miR-33b*) and determined the resulting transcriptional profile (Figure S2A). Cluster analyses 
of these RNA profiles indicated that miR-302d and miR-373-3p had similar effects in terms of 
target gene regulation (Figure S2B), as expected from their common seed sequence. The 
genes that were either downregulated (n=96 in total) or upregulated (n=156) by all six 
miRNAs are shown in Figure S2C. The effects of these miRNAs on the genes involved in the 
Hippo pathway are reported in Table S1 and summarized in Figure S2D, in which the levels 
of each of the differentially regulated transcripts in the Hippo pathway is shown along its fold 
difference over control (green: downregulated genes; red: upregulated genes). While this 
RNA-seq analysis, being performed on a single replicate, did not possess statistical 
significance of the differentially expressed genes under each miRNA transfection, it however 
permitted to indicate common genes and pathways shared by all miRNAs. The concordant 
information between RNAseq and target prediction is summarized in the cartoon shown in 
Figure 2A. Based on this information, we then focused our attention on the mechanism of 
action of the individual miRNAs. 
Previous work has already shown that miR302-367 downregulates MST1, LATS2 and 
MOB1b in the Hippo pathway (Tian et al., 2015). As far as miR-199a-3p is concerned, CM 
treatment with this miRNA resulted in the downregulation both the TAO kinase1 (TAOK1) 
and the E3 ubiquitin-ligase -transducing repeat containing protein (-TrCP); Figure S2D. 
TAOK1/3 was reported to phosphorylate and activate MST1/2 (Boggiano et al., 2011), as well 
as to act as direct kinases for LATS1/2 (Plouffe et al., 2016; Poon et al., 2011); -TrCP instead 
catalyzes phosphorylated YAP ubiquitination, ultimately leading to its degradation (Zhao et 
al., 2010) (cartoon in Figure 2A). We experimentally verified that CM treatment with miR-
199a effectively downregulated the mRNAs for these two proteins (Figure 2B). In addition, 
we noticed that the STK38L kinase was a predicted target for 5 of the investigated miRNAs 
and that its levels were downregulated in all 6 RNAseq profiles. We thus experimentally 
verified that the STK38L mRNA was reduced upon CM treatment with the tested six 
miRNAs, including miR-33b*, which was not predicted bioinformatically, but with the 
exception of miR-590-3p (Figure 2C). Consistent with the information that miR-199a-3p 
downregulates the mRNAs coding for TAOK1, -TrCP and STK38L we also found that the 
levels of the respective proteins were reduced in CMs treated with this miRNA (representative 
blot and quantification in Figures 2D and 2E respectively). 
Next, we assessed whether TAOK1, -TrCP and STK38L are direct targets of the investigated 
miRNAs. For this purpose, we cloned the 3’UTRs of the three genes downstream of the 
Renilla luciferase mRNA and transfected these plasmids into HeLa cells treated with the 10 
pro-proliferative miRNAs. Simultaneous transfection of a plasmid encoding for firefly 
luciferase served as a transfection control, while the empty cloning vector (psiCheck2.1) was 
used for normalization (scheme in Figure 2F).  
Analysis of luciferase activity after 48 h revealed that both TAOK1 and -TrCP, but none of 
the other investigated miRNAs, were direct targets of miR-199a-3p (Figures 2G and 2H 
respectively, for the results with miR-199a only, and Figure S3A and Figure S3D for results 
will all the 10 pro-proliferative miRNAs), while none of the miRNAs targeted directly the 
3’UTR of STK38L (Figure 3I for the 6 miRNA that downregulate STK38L mRNA and 
Figure S3G for all the 10 miRNAs). Sequence analysis of the TAOK1 and -TrCP 3’UTRs 
revealed the presence of potential target sites for miR-199a-3p (Figure S3B and S3E 
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respectively). Mutation of these sites abrogated the downregulation effect for both genes, thus 
supporting the specificity of the miRNA-target mRNA interaction (Figure S3C and S3F). 
Next, we investigated whether the downregulation of TAOK1, -TrCP or STK38L exerts a 
direct role in the regulation of CM proliferation. First, we generated siRNAs targeting each of 
the three genes; these siRNAs downregulated expression of the respective proteins, >90% in 
the case of TAOK1, >70% in the case of -TrCP and >50% in the case of STK38L, compared 
to control (representative blots and quantification in Figures 2J and 2K respectively). Then 
we transfected these siRNAs in CMs and tested their proliferation. We found that the siRNAs 
against TAOK1 and -TrCP stimulated CM EdU incorporation; their effect was suppressed by 
the simultaneous downregulation of YAP by RNAi (Figure 2L). In contrast, the individual 
siRNA against STK38L was ineffective. Figure S4 displays some representative images of 
CMs treated with siRNAs against TAOK1 and -TrCP, with or without the siRNA against 
YAP. Consistent with these findings, we also found that the downregulation of TAOK1 and -
TrCP activated expression, in CMs, of the TEAD-responsive promoter (Figure 2M).  
Taken together, these results reveal that the mechanism by which miR-199a-3p induces CM 
proliferation involves the direct targeting of two proteins, TAOK1 and -TrCP, which 
individually participate in the regulation of YAP activity and the control of CM proliferation. 
 
Modulation of the actin cytoskeleton by Cofilin-2 regulates cardiomyocyte proliferation 
While performing the above described experiments, we reproducibly noticed that CMs treated 
with some of the pro-proliferative miRNAs (most notably, miR-199a-3p and miR-373) 
induced a remarkable modification of cell shape. We thus wanted to examine the actin 
cytoskeleton using fluorescein-tagged phalloidin to visualize F-actin. In control cells treated 
with the C. elegans miR-67, actin was organized regularly in long threads throughout the 
cytoplasm, overlapping with those of the CM-specific, sarcomeric -actinin (Figure 4A). In 
contrast, cells treated with miR-199a-3p and miR-373 were round-shaped, with actin fibers 
assembled in round bundles close to the cytoplasm periphery; these bundles of cortical actin 
were particularly evident in -actinin-negative cells (fibroblasts). CMs treated with the two 
miRNAs also showed reduced organization of the sarcomere. No effect was instead detected 
in cultures treated with miR-590-3p. Figure 4B reports quantification of the number of round-
shaped CMs upon miRNA treatment. 
To follow up on this observation, we generated a catalogue of 79 genes known to participate 
in, or regulate, formation of the microfilament cytoskeleton (Table S2). For each of these 
genes, we annotated the predicted targeting of each of the investigated miRNAs and the extent 
of downregulation observed after CM treatment with each miRNA. The genes that were 
differentially regulated are shown in Figure S2D. These included various members of the 6 
regulatory families coding for factors that normally prevent unwanted actin polymerization by 
directly interacting with G-actin, including Cofilin2 (Cfl2), Twinfilin1 and Twinfilin2 (Twf1 
and Twf2), Thymosin 4 (Tmsb4x) and Profilin2 (Pfn2) (Xue and Robinson, 2013). 
Additionally downregulated proteins were Csrp3, Mical3 and Aurora A kinase (Aurka), all of 
which are directly or indirectly involved in the regulation of actin polymerization (Fremont et 
al., 2017; Papalouka et al., 2009; Ritchey and Chakrabarti, 2014). Figure 3C shows that 
several of these proteins were also predicted direct targets of the miRNAs by computational 
algorithms. 
We focused our attention on the Cofilin2 mRNA, which was downregulated by all the 
investigated miRNAs, with the exception of miR-590-3p, and was the predicted target of 4 of 
these miRNAs (miR-199a-3p, miR-1825, miR-302d and miR-373). Indeed, we found that all 
these 4 miRNAs targeted the Cofilin2 3’UTR in UTR-luciferase assays (Figure 3D).  
Quantification of mRNA levels in miRNA-treated CMs confirmed significant downregulation 
of the Cofilin2 mRNA in cells treated with these 4 miRNAs, in addition to CMs also treated 
with miR-33b* (Figure 3E). Downregulation of Cofilin2 by the last miRNA is likely an 
indirect effect or an effect exerted through binding of the miRNAs to portions of the Cofilin2 
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mRNA outside the 3’UTR. Analysis of Cofilin2 protein levels in miRNA-treated CMs 
provided consistent results showing downregulation of this factor after treatment with miR-
199a-3p, miR-1825, miR-302d and miR-373 (Figure 3F). Sequence analysis of the Cofilin2 
mRNA 3’UTRs revealed the presence of a potential target site for miR-199a-3p. Mutation of 
this site abrogated the downregulation effect for this miRNA, thus supporting specificity 
(Figures S3H and S3I). 
Finally, we observed that a similarly rounded shape and spatial arrangement of F-actin was 
also detected in cells transfected with the anti-Cofilin2 siRNA (representative images and 
quantification in Figures 3G and 3H respectively). 
Collectively, these results indicate that proteins regulating the actin cytoskeleton dynamics and, 
in particular, the inhibitor of F-actin polymerization Cofilin2, are frequently targeted, either 
directly or indirectly, by miRNAs that induce CM proliferation. 
 
Remodeling of the actin cytoskeleton in proliferating cardiac myocytes 
Cofilin2 regulates the actin cytoskeleton by promoting conversion of polymerized F-actin 
back into its monomeric, G-actin, form. We thus assessed the ratio between G- and F-actin in 
CMs treated with a few of the pro-proliferative miRNAs or with an siRNA against Cofilin2; 
this siRNA downregulated the levels of its target protein by >60% in CMs, as well as 
upregulated the levels of F-actin, as shown by western blotting (Figure 4A).  
The G/F ratio resulted decreased for CMs treated with all the tested miRNAs; this result  
reached statistical significance for miR-199a-3p, miR-373, miR-302d and miR-33b* when 
compared to the C. elegans miRNA control. The G/F ratio was also decreased in cells treated 
with the anti-Cofilin2 siRNA (Figure 4B for representative blots and Figure 4C for 
quantification).  
Progression of the cell cycle towards G2 and mitosis was assessed in cells treated with miR-
199a-3p, miR-590-3p, miR-373 or the anti-Cofilin2 siRNA by visualizing phospho-histone H3. 
As shown in the representative pictures in Figure 5A for the miRNAs and Figure 5B for the 
siRNA, and quantified in Figure 5C, all treatments induced 5-9% of the cells to travel through 
the G2/M phase. Mitotic CMs showed disruption of the sarcomeric architecture, as concluded 
from the diffused staining with -actinin shown in Figure 5D. Alpha-actinin-positive CMs in 
different phases of mitosis are shown in Figure 5E. 
 
Downregulation of Cofilin2 activates cardiomyocyte proliferation through YAP 
activation 
We asked whether activation of CM proliferation upon downregulation of Cofilin2 and actin 
cytoskeleton rearrangement might directly involve activation of YAP. Supporting this 
possibility, we found that, in CMs, downregulation of Cofilin2 by RNAi determined 
transcriptional activation of the TEAD-dependent, YAP-responsive promoter (Figure 6A). 
Simultaneous transfection of CMs with an siRNA against YAP abrogated the pro-proliferative 
effect exerted by Cofilin2 downregulation, similar to its inhibitory effect on miR-199a-3p 
(Figure 6B; representative picture showing decreased number of cells incorporating EdU in 
Figure 6C). Finally, CM treatment with the anti-Cofilin2 siRNA showed marked activation of 
the mRNA levels of two well-established YAP-responsive genes, CTGF and CyR61(Zhao et 
al., 2008); (Figure 6D). 
The above results are suggestive of a correlation between the extent of actin polymerization 
(which is increased by Cofilin2 inhibition) and the activation of YAP. To further explore this 
link, we inversely inhibited actin polymerization using cytochalasin D, and then studied the 
levels of nuclear and cytoplasmic YAP. We found that CMs treated with this drug (which, as 
expected, also completely blocked EdU incorporation; data not shown), reduced the levels of 
nuclear YAP in a time-dependent manner, while increasing the amounts of the cytoplasmic, 
phosphorylated protein (representative western blots in Figure 6E and quantification in 
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Figure 6F). This effect resulted in marked suppression of the levels of the CTFG and CyR61 
gene mRNAs (Figure 6G). On the contrary, CM treatment with the actin cytoskeleton 
stabilizing drug jasplakinolide (Wang et al., 2014a), when used at concentrations that were not 
toxic to the cells, significantly increased the levels of nuclear YAP1 (Figure S5). 
Together, these results are consistent with the conclusion that, in CMs, the extent of actin 
polymerization regulates YAP nuclear activity and, as a consequence, controls the levels of 
cell proliferation. 
Finally, we observed that nuclear translocation of YAP and activation of YAP-reporter genes 
was specific for miR-199a and cell treatment with the pro-hypertrophic drug phenylephrine, 
consistent with published results (Del Re et al., 2013; Wang et al., 2014b), while did not occur 
upon CM treatment with a combination of FGF1 and a p38 inhibitor, a stimulus previously 
reported to also induce CM proliferation (Engel et al., 2005); Figure S6. These results 
confirmed specificity of the observed effects relating miRNA treatment with YAP activation. 
 
DISCUSSION 
 
In this work, we have described the mechanisms of action of a series of miRNAs that were 
recently shown to induce CM proliferation, and are thus of interest for potential applications 
aimed at stimulating cardiac regeneration. In essence, the information that we obtained 
indicates that all these miRNAs converge in the activation of nuclear translocation of the YAP 
transcriptional coactivator. This event is however achieved through the modulation of the 
levels of different effector genes, among which the regulation of actin cytoskeleton dynamics 
plays an essential role. 
The proliferative miRNAs act through different pathways to achieve convergent YAP 
activation. Among the factors that are downregulated either directly or indirectly are one or 
more of the cellular kinases known to inactivate YAP, in particular TAOK1, LATS1/2 and 
STK38L. Our results show that miR-199a directly targets the 3’UTR of TAOK1; previous 
work indicated that the miR-302/367 cluster (of which we analyzed miR-302c and miR-302d) 
downregulates the levels of MST1 and MOB1b, in addition to those of LATS2 (Tian et al., 
2015). The levels of STK38L instead resulted downregulated upon CM treatment with 5 
different miRNAs, but in no case we could detect direct targeting of the factor mRNA 3’UTRs, 
indicating that either the effect is indirect or that it is exerted through binding of the miRNAs 
to different regions of the kinase mRNA. Convergence of CM pro-proliferative miRNAs onto 
the Hippo pathway was also recently shown by the Mercola laboratory after high throughput 
screening for miRNAs stimulating human iPS cell-derived CM proliferation (Diez-Cunado et 
al., 2018). 
MiR-199a-3p directly targeted the 3’UTR of TAOK1 and TrCP, the latter acting as the E3 
ubiquitin ligase driving YAP degradation through the proteasome (Zhao et al., 2010). Of 
interest, individual downregulation of either TAOK1 or TrCP by RNAi was sufficient to 
stimulate CM proliferation, indicating that the effect of miR-199a is likely the combinatorial 
outcome of the downregulation of these (and other) genes impacting on the same pathway. 
Given that TAOK1 and, in particular, TrCP (Fuchs et al., 2004) are involved in several 
cellular processes, it might well be envisaged that miR-199a might also exert additional 
functions in CMs in addition to stimulating their replication.  
Besides the Hippo pathway, another molecular signature common for several of the 
investigated miRNAs was the modulation of the actin cytoskeleton network. In particular, we 
observed a shift in the balance between F- and G-actin towards the polymerized state for all 
the miRNAs, in particular for miR-199a-3p, miR-302d, miR-373 and miR-33b*. Consistent 
with this effect, cells treated with miR-199a-3p or miR-373 microscopically showed a rounded 
morphology and displayed formation of layers of cortical, polymerized actin in bundles close 
to the cytoplasm periphery.  
An actin-regulatory protein that was downregulated by treatment with all the miRNAs, with 
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the exception of miR-590-3p, was Cofilin2. This protein is a muscle-specific member of the 
ADF/Cofilins family of proteins, which is essential to modulate actin filament non-
equilibrium assembly and disassembly, and is thus involved in all aspects of cell motility, 
locomotion and invasion (Bernstein and Bamburg, 2010; Bravo-Cordero et al., 2013). In 
particular, Cofilin binds actin monomers and filaments, causing depolymerization of actin 
filaments and preventing their reassembly (Ghosh et al., 2004). Of note, four of the miRNAs 
that we investigated (miR-199a-3p, miR-1825, miR-302d and miR-373) directly targeted the 
Cofilin2 3’UTR. Even more notably, the downregulation of Cofilin2 itself by a specific 
siRNA was sufficient to stimulate CM proliferation and to activate YAP nuclear translocation 
and transactivation of YAP-target genes, while inhibition of actin polymerization by 
cytochalasin D (a potent inhibitor of actin polymerization) blocked this effect. These results 
are consistent with previous findings in other cell types showing that the actin cytoskeleton 
dynamics is a strong activator signal for YAP in response to mechanical cues ensuing from 
the extracellular environment (Dupont et al., 2011).  
The interplay between YAP activation and the cytoskeletal arrangement of CMs has an 
additional layer of complexity, since recent work has shown that YAP directly regulates 
genes encoding for proteins that promote F-actin polymerization and link the actin 
cytoskeleton to the extracellular environment, including components of the dystrophin 
glycoprotein complex (Morikawa et al., 2015). A component of this complex, Dag1, directly 
binds YAP and inhibits its pro-proliferative function (Morikawa et al., 2017). Since the 
dystrophin glycoprotein complex connects the extracellular matrix to the actin cytoskeleton, it 
is conceivable that perturbing integrity of this connection at different levels might lead to 
YAP activation.  
The discovery that individual miRNAs regulate post-natal CM proliferation is of particular 
interest towards the potential utilization of these molecules to promote cardiac regeneration. 
The identification of the molecular targets of the pro-proliferative miRNA is particularly 
important in this context. The results presented here indicate that stimulation of CM 
proliferation by miRNAs is a process that requires multiple targeting with likely additive 
effect. In this respect, the pleiotropic effect of miRNAs appears to be of significant advantage 
compared to the use of single genes or siRNA knockdowns, provided that the potential 
deleterious effects are minimized. For example, miR-199a-3p, one of the most effective 
miRNAs both ex vivo and in vivo, targets directly the 3’UTRs of Cofilin2 (modulation of 
actin cytoskeleton), TAOK1 (activation of the YAP inhibitory kinases) and TrCP 
(reduction of YAP degradation), in addition to the 3’UTRs of Hopx1 (a suppressor of 
embryonic CM proliferation (Trivedi et al., 2010) and Homer1 (involved in the regulation of 
calcium signaling in cardiac cells (Jardin et al., 2013), as shown in our previous work (Eulalio 
et al., 2012); additional mRNAs could be targeted as well. 
Despite this pleiotropic gene downregulation, however, it is of notice that all the pro-
proliferative pathways appear to converge, and require, YAP activation. This conclusion is 
consistent with our previous observation, unexplained at the time, that combinatorial 
combinations of the four most effective miRNAs in our original HTS screen did not exert an 
effect that was superior to that of each individual miRNA when used at the same 
concentration of the combined molecules (Eulalio et al., 2012).  
While the pleiotropic function of miRNAs appears highly desirable to stimulate a complex 
biological event such as differentiated CM proliferation, yet these molecules need to be 
considered with caution in translational terms. While the permanent expression of miR-199a 
and miR-590 pri-miRNAs using AAV9 vectors in the mouse did not result in apparent 
deleterious effects (Eulalio et al., 2012), permanent expression of the miR-302/367 cluster led 
transgenic animals to develop cardiac dysfunction due to CM hyperproliferation coupled with 
cell de-differentiation (Tian et al., 2015). This is consistent with the observation that miR-
302/367 enhances the reprogramming efficiency of mouse embryonic fibroblasts into induced 
pluripotent stem cells (iPSCs) (Judson et al., 2009; Li et al., 2011). In addition, recent work 
from our laboratory has shown that cardiac delivery of miR-199a after myocardial infarction 
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in pigs using a viral vector driving its persistent expression stimulates cardiac regeneration in 
the first month after treatment, however causes sudden arrhythmic deaths in several of the 
treated animals at longer observation (Gabisonia et al., 2019). Thus, the permanent expression 
of these molecules does not appear desirable for the unwanted effects they may cause.  
This note of caution, however, does not rule out that appropriate dose and schedule for the 
delivery of synthetic miRNA mimics, in contrast to permanent expression, would be effective 
and well tolerated. Available evidence already shows that single dose, systemic injection of 
miR302b/c (Tian et al., 2015) or intracardiac injection of miR-199a-3p mimics (Lesizza et al., 
2017) determine significant beneficial effect in terms of recovery of myocardial tissue and 
function in mice. These observations warrant further translation of synthetic pro-regenerative 
miRNAs to large animals first and to the clinics later.  
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FIGURE LEGENDS 
 
Figure 1. Activation of YAP mediates activity of miRNAs that induce cardiomyocyte 
proliferation 
A. Experimental scheme to test activation of TEAD-dependent transcription. B. TEAD-
luciferase reporter analysis of CMs transfected with the indicated miRNA mimics. 
Transfection efficiency was standardized over a constitutively expressed Renilla luciferase 
reporter. Transfection of a constitutively active YAP plasmid (pYAP5SA) served as a positive 
control. Data are mean±SEM (n=5 independent experiments); * P<0.05, **P< 0.01; one-way 
ANOVA. C. Induction of YAP nuclear translocation by treatment of CMs with pro-
proliferative miRNAs. The western blots show the levels of nuclear and cytoplasmic YAP1 
and phospho-YAP1 (P-YAP1) 72 hr after transfection in a representative experiment. PARP1 
and GAPDH were used for loading control of the nuclear and cytoplasmic fractions 
respectively. D. Quantification of YAP nuclear translocation in CMs after miRNA mimics 
transfection. Results are shown as a ratio of YAP to nuclear PARP1. Data are mean±SEM 
(n=5 independent experiments); * P<0.05, **P< 0.01; one-way ANOVA. E. Efficacy of 
YAP1 downregulation using a specific siRNA. On the left side, representative western 
blotting. On the right side, quantification of 3 independent experiments. Data are mean±SEM; 
**P< 0.01; t-test. F. Induction of CM proliferation by miRNA mimics is blunted by YAP 
knockdown. CMs were transfected with pro-proliferative microRNAs alone or in combination 
with an anti-YAP siRNA or the same amount of a non-targeting siRNA. The graph shows the 
percentage of sarcomeric α-actinin-positive cells that have incorporated EdU in a 72 hr period. 
Data are mean±SEM (n=4 independent experiments); * P<0.05, **P< 0.01; one-way 
ANOVA. G. Representative images of CMs treated with the indicated miRNAs with or out 
without a siRNA against YAP. Scale bar: 100 µm. 
 
Figure 2. Mechanism for YAP activation by miR-199a-3p and other miRNAs. A. 
Schematic representation of the Hippo pathway with the indication of the predicted target 
proteins according TargetScan software predictions. B. Real-time RT-PCR quantification of 
TAOK1 and TrCP mRNAs in CMs treated with miR-199a-3p mimic. Data are mean±SEM 
of 3 independent experiments; *P<0.05; t-test. C. Real-time RT-PCR quantification of 
STK38L mRNA levels in CMs treated with the indicated miRNA mimics. Data are 
mean±SEM of 3 independent experiments; *P<0.05; one-way ANOVA. D and E. 
Representative western blots (D) and quantification (E) showing downregulation of TAOK1, 
TrCP and STK38L proteins in cells treated with miR-199a-3p mimic. Data are mean±SEM 
of 3 independent experiments; *P<0.05; t-test. F. Experimental flow chart of 3'UTR 
luciferase assays. Fluc and Rluc: firefly and Renilla luciferase genes respectively. G and H. 
TAOK1 (G) and TrCP (H) are direct targets of miR-199a-3p. Results of 3'UTR luciferase 
assays with miR-199a-3p. Renilla luciferase (Rluc) values were normalized over firefly (Fluc) 
values to standardize for transfection efficiency. Control refers to transfection of a Renilla 
luciferase gene with no 3'UTR. Data are mean±SEM (n=3 independent experiments); 
*P<0.05; t-test. I. Results of 3’-UTR assays for STK38L in cells transfected with the 
indicated miRNA mimics. J and K. Representative western blots (J) and quantification (K) 
showing downregulation of TAOK, TrCP and STK38L in CMs transfected with the 
respective siRNAs. L. Downregulation of TAOK1 and β-TrCP stimulates CM proliferation in 
a YAP-dependent manner. The graph shows the percentage of sarcomeric α-actinin-positive 
cells that have incorporated EdU in a 72 hr period after treatment with specific siRNAs alone 
or in combination with an anti-YAP siRNA. Data are mean±SEM (n=4 independent 
experiments); * P<0.05, **P< 0.01; one-way ANOVA. M. Downregulation of TAOK1 and 
TrCP stimulate transcriptional TEAD activity. CMs were transfected with siRNAs against 
TAOK1 or β-TrCP in combination with a TEAD-firefly luciferase reporter. The results were 
normalized to those of a constitutively expressed Renilla luciferase construct. Data are 
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mean±SEM over a non-targeting (NT) siRNA (n=5 independent experiments); * P<0.05; one-
way ANOVA.  
 
Figure 3. Treatment of CMs with miRNAs downregulates Cofilin2 and induces 
remodeling of the actin cytoskeleton. 
A. Immunofluorescence pictures showing remodeling of the actin cytoskeleton upon miRNA 
treatment. F-actin is visualized using fluorescent phalloidin (green), CMs with an anti- -
actinin antibody (red), nuclei with Hoechst (blue). F indicates fibroblasts (-actinin negative 
cells). B. Percentage of CMs with a rounded shape (as in the representative images in Panels 
A) after treatment of CMs with the indicated miRNAs. Data are from the analysis of over 400 
CMs from four different experiments; shown are mean±SEM; ** P <0.01; one-way ANOVA. 
C. Simplified view of proteins involved in actin cytoskeleton remodeling which are predicted 
to be targeted by the indicated pro-proliferative miRNAs. D. Results of 3'UTR assays to 
evaluate direct targeting of Cofilin2 (Cfl2) by the investigated miRNAs. Experiments were 
performed as in Figure 2F. Data are mean±SEM (n=3 independent experiments); *P <0.05; 
**P <0.01; one-way ANOVA. E. Results of real-time RT-PCR quantification of the Cofilin2 
mRNA in CMs treated with the indicated miRNA mimics. An siRNA against Cofilin2 (siCfl2) 
was used as a positive control. Data are mean±SEM (n=3 independent experiments); * 
P<0.05; ** P <0.01; one-way ANOVA. F. Effect of miRNAs on Cofilin2 protein levels in 
CMs. Strip in the upper part: Representative western blot showing downregulation of Cofilin2 
in CMs transfected with the indicated miRNA mimics. Graph in the lower part: quantification 
of the levels of Cofilin2. Data are mean±SEM (n=3 independent experiments); * P<0.05; ** P 
<0.01; one-way ANOVA. The dotted, red line shows the levels Cofilin2 in CMs treated with 
the control cel-miR-67 miRNA. G. Same as in panel A in CMs treated with an anti-Cofilin2 
siRNA or with a non-targeting (NT) siRNA control. H. Percentage of CMs with a rounded 
shape (as in the representative images in Panel G) after treatment of CMs with the Cofilin2 
siRNA. Data are from the analysis of over 400 CMs from four different experiments; shown 
are mean±SEM; **P <0.01; t-test. 
 
Figure 4. Treatment of CMs with miRNAs induces remodeling of the actin cytoskeleton. 
A. Representative western blot showing that downregulation of Cofilin2 increases the levels 
of filamentous- (F-)actin. siRNA NT: non-targeting siRNA control B. Quantification of the 
G-actin/F-actin ratio in CMs treated with the indicated pro-proliferative miRNAs or with anti-
Cofilin2 siRNA. The pictures show representative western blots, using an anti--actin 
antibody, of supernatants (containing G-actin) and pellets (F-actin) obtained by 
ultracentrifugation of lysates from the treated CMs. The G/F ratio is shown at the bottom of 
each band pair. The positive (+) control was provided by the kit manufacturer. C. 
Quantification of the G/F actin ratio, expressed in percentage, obtained as in panel B. Data are 
mean±SEM (n=3 independent experiments); * P<0.05; ** P <0.01; one-way ANOVA. The 
dotted, red line shows the G/F ratio in CMs treated with the control cel-miR-67 miRNA.  
 
 
Figure 5. Disruption of the sarcomeric architecture in mitotic cardiomyocytes treated 
with miR-199a-3p and Cofilin2 siRNA. A and B. Representative pictures showing G2/M 
cells upon treatment with miR-199a-3p (panel A) or anti-Cofilin2 siRNA (panel B), showing 
nuclear positivity for phospho-histone H3 (pH3(S10), red) and diffused cytoplasmatic staining 
for -actin (green). Nuclei are counterstained with Hoechst 33342 (blue). C. Percentage of 
pH3(S10)+, -actinin+ cells (CMs) after treatment with the indicated miRNAs or Cofilin2 
siRNA. Cel-miR-67 and a non-targeting (NT) siRNA served as negative controls for miRNA 
and siRNA experiments respectively. Data are from the analysis of over 400 CMs from four 
different experiments; shown are mean±SEM; ** P <0.01, * P <0.05; one-way ANOVA. D. 
Representative pictures of G2/M CMs (defined as in panel C), showing nuclear positivity for 
phospho-histone H3 (pH3(S10), red) and disruption of the sarcomeric architecture, as 
concluded from diffused staining of -actinin (red). Nuclei are counterstained with Hoechst 
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33342 (blue). E. Mitotic CMs in subsequent phases of mitosis (from a to d). Staining is as in 
panel D. 
 
Figure 6. Perturbation of the actin cytoskeleton activates YAP nuclear translocation and 
activity. A. Downregulation of Cofilin2 activates TEAD reporter activity. The graph reports 
the results of TEAD-firefly luciferase reporter analysis of CMs transfected with miR-199a-3p 
and Cofilin2 siRNA. Experiments were performed as in Figure 1A. Transfection efficiency 
was standardized over a constitutively expressed Renilla luciferase reporter. Data are 
mean±SEM (n=4 independent experiments); * P<0.05, **P< 0.01; one-way ANOVA. B. 
Downregulation of Cofilin2 activates CM replication in a YAP-dependent manner. The graph 
shows the percentage of α-actinin-positive cells that have incorporated EdU in a 72 hr period 
after treatment with anti-Cofilin2 siRNA or miR-199a-3p mimic alone or in combination with 
an anti-YAP siRNA. Data are mean±SEM (n=4 independent experiments); * P<0.05, ** 
P<0.01; one-way ANOVA. C. Representative pictures showing CMs incorporating EdU after 
treatment with an anti-Cofilin2 siRNA as in Panel B in the absence or presence of an anti-
YAP siRNA. D. Real-time RT-PCR analysis of the levels of the two TEAD responsive genes 
CTFG and CyR61 in CMs transfected with anti-Cofilin2 siRNA. Data are mean±SEM (n=4 
independent experiments); ** P <0.01; t-test. E. Treatment of CMs with cytochalasin D 
blocks nuclear translocation of YAP. Representative blots showing the levels of nuclear and 
cytoplasmic YAP1 and phospho-YAP1 (P-YAP1) in CMs treated with cytochalasin D for the 
indicated time points. GAPDH and p84 were used for loading controls of cytoplasmic and 
nuclear fractions respectively. F. Quantification of YAP nuclear translocation in CMs treated 
with cyochalasin D. Data are mean±SEM (n=3 independent experiments); **P<0.01; one-
way ANOVA. G. Treatment with cytochalasin D blocks transcription of YAP- responsive 
genes. The graph shows the levels of the CTFG and CyR61 mRNAs, measured by real-time 
RT-PCR, in CMs treated with cyochalasin D for the indicated time points. Data are 
mean±SEM (n=3 independent experiments). All times showed statistical significance at 
P<0.01; one-way ANOVA. 
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STAR METHODS 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal anti-YAP Cell Signaling 
Tecnology 
Cat# 4912S 
RRID:AB_1069468
2 
Rabbit polyclonal anti-Phospho YAP (Ser 127) Cell Signaling 
Tecnology 
Cat# 4911S 
RRID:AB_2218913 
Rabbit polyclonal anti-Cofilin 2 Millipore Cat# 07-300 
RRID:AB_2080926 
Mouse monoclonal anti-F actin Abcam Cat# ab205 
RRID:AB_302794 
Clone NH3 
Rabbit polyclonal anti-alpha-actin Cytoskeleton 
 
Cat# AAN01 also 
AAN01-B,AAN01-
A 
RRID:AB_1070807
0 
Rabbit polyclonal anti--TrCP/HOS 
 
Santa Cruz 
Biotechnology 
 
Cat# sc-15354 
RRID:AB_2065916 
Rabbit polyclonal anti-GAPDH Santa Cruz 
Biotechnology 
Cat# sc-25778 
RRID:AB_1016766
8 
 
Rabbit polyclonal anti-PARP-1 Enzo Life Sciences Cat# ALX-210-302 
RRID:AB_2160732 
 
Mouse monoclonal anti-p84 Abcam Cat# ab487 
RRID:AB_304696 
Clone 5E10 
Mouse monoclonal anti-Sarcomeric Alpha Actinin Abcam Cat# ab9465 
RRID:AB_307264 
Alexa fluor 488 phalloidin Thermo Fisher 
Scientific 
 
Cat# A12379 also 
A-12379 
RRID:AB_2315147 
Rabbit polyclonal anti-TAOK1 LifeSpan BioSciences, 
Inc. 
Cat# LS-C146952 
Lot# 62983 
RRID:AB_1113255
8 
Rabbit polyclonal anti-STK38L/Ndr2 
 
Abcam Cat# ab126106 
RRID:AB_1112955
6 
Chemicals, Peptides, and Recombinant Proteins 
FuGENE HD Transfection Reagent Promega Cat#E2312 
Cytochalasin D, 1mM Santa Cruz Cat#sc-201442 
Oligofectamine Thermo Scientific Cat#12252011 
RNAiMAX Thermo Scientific Cat#13778150 
Jasplakinolide  Sigma Cat#J4580  
Bovine FGF acidic Protein R&D Systems Cat#132-FA 
P38 inhibitor Calbiochem Cat#SB203580 
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Phenylephrine Sigma Cat#P6126 
Critical Commercial Assays 
G-actin/F-actin In Vivo Assay kit Cytoskeleton, Inc Cat#BK037 
Dual-Glo Luciferase assay System Promega Cat#E2940 
Click-IT EdU Alexa Fluor 594 Imaging kit Thermo Scientific Cat#C10339 
CTGF  TaqMan Gene Expression Assay Thermo Scientific Assay ID 
Rn01537279_g1 
CyR61 TaqMan Gene Expression Assay Thermo Scientific Assay ID 
Rn00580055_m1 
TAOK1 TaqMan Gene Expression Assay Thermo Scientific Assay ID 
Rn00597907_m1 
-TrCP TaqMan Gene Expression Assay Thermo Scientific Assay ID 
Rn01413748_m1 
Cfl2    TaqMan Gene Expression Assay Thermo Scientific Assay ID 
Rn01472820_g1 
STK38L    TaqMan Gene Expression Assay Thermo Scientific Assay ID 
Rn01472820_g1 
Deposited Data 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of hsa-miR-302d 
This Study Accession 
GSM3716799 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of hsa-miR-373-3p 
This Study Accession 
GSM3716798 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of hsa-miR-33b* 
This Study Accession 
GSM3716800 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of hsa-miR-1825 
This Study Accession 
GSM3716801 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of hsa-miR-199a-3p 
This Study Accession 
GSM3716796 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of hsa-miR-590-3p 
This Study Accession 
GSM3716797 
mRNA sequence data of neonatal rat cardiomyocytes 
after transfection of cel-miR-67 
This Study Accession 
GSM3716795  
Experimental Models: Cell Lines 
HeLa cell line ATCC Cat# CCL-2, 
RRID:CVCL_0030 
Experimental Models: Organisms/Strains 
Wistar neonatal Rat  Harlan N/A 
Oligonucleotides 
siRNA YAP1sense: 5'- 
GGAGAAGUUUACUACAUAA [dT] [dT] -3'  
Sigma siRNA targeting 
sequence: YAP1  
NM_001034002.2 
siRNA YAP1 antisense: 5'-
UUAUGUAGUAAACUUCUCC [dT] [dT] -3' 
Sigma siRNA targeting 
sequence: YAP1  
NM_001034002.2 
siGenome SMARTpool against rat Cfl2  Dharmacon cat# M-099723-01 
siGenome SMARTpool against rat TAOK1  Dharmacon cat# M-095482-01 
siGenome SMARTpool against rat -TrCP  Dharmacon cat# M-086092-01 
siRNA against rat STK38L  Sigma ID: SASI 
Rn02_00208859  
MISSION siRNA Universal Negative Control #1 Sigma Cat#SIC001 
siGENOME Non-Targeting siRNA #4 Dharmacon Cat#D-001210-04 
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Recombinant DNA 
p8xGTIIC-Luc plasmid  Gift from Stefano 
Piccolo, University of 
Padova 
Addgene, Cat#34615 
pRL Renilla Luciferase control plasmid Promega cat# E2261 
5SA-YAP1 in pCSII-EF-MCS plasmid Gift from Stefano 
Piccolo, University of 
Padova 
N/A 
psiCheck2.1 plasmid Promega Cat# C8021 
3’UTR-Cfl2 plasmid Biomatik Clone ID T4545-1 
3’UTR--TrC plasmid Genewiz Clone ID B28633-
1/K28633 
3’UTR-TAOK1 plasmid Genewiz  
3’UTR-mut TAOK1 plasmid QuikChange II XL 
Site-Directed 
Mutagenesis Kit 
N/A 
3’UTR-mut -TrC plasmid QuikChange II XL 
Site-Directed 
Mutagenesis Kit 
N/A 
3’UTR-STK38L plasmid IDT gblock N/A 
3’UTR-Cfl2mut plasmid IDT gblock N/A 
Software and Algorithms   
Clustering algorithm   www.scipy.org Jones E, Oliphant E, 
Peterson P, et 
al. SciPy: Open 
Source Scientific 
Tools for Python, 
2001 
Functional analysis  https://david.ncifcrf.go
v 
(Huang da et al., 
2009a, b) 
FASTQC software http://www.bioinform
atics.babraham.ac.uk/p
rojects/fastqc 
N/A 
Cutadapt software  (Martin, 2011) 
STAR software  (Dobin et al., 2013) 
Bioconductor package edgeR rpkm function  (McCarthy et al., 
2012) 
Rattus Norvegicus reference genome  GCF_000001895.5  
Rnor 6.0.82 
N/A 
TargetScan Software release 7.1 www.targetscan.org N/A 
miRBase 21 database www.mirbase.org N/A 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and request for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Mauro Giacca (mauro.giacca@kcl.ac.uk) 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Animal studies 
Animal care and treatment were conducted in conformity with institutional guidelines after 
approval by the ICGEB Institutional Review Board following consent from the Italian 
Ministry of Health in accordance with the Italian law (D.lgs. 26/2014), following European 
Union policies (European and Economic Council Directive 86/609, OJL 358, December 12, 
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1987). 
 
 
Isolation of ventricular cardiomyocytes  
Ventricular CMs were isolated from both male and female neonatal rats as previously 
described (Collesi et al., 2008). Briefly, ventricles from neonatal (P0) rats were separated from 
the atria, cut into pieces and then dissociated in calcium and bicarbonate-free Hanks with 
Hepes (CBFHH) buffer containing 1.75 mg/ml trypsin (BD Difco) and 10 mg/ml DNase II 
(Sigma), using mechanical and physical stirring. Digestion was performed at room 
temperature in ten 10-min steps with collection of the supernatant to fetal bovine serum (FBS, 
Life Technologies) after each step. The collected supernatant was centrifuged to pellet the 
cells, which were then resuspended in Dulbecco’s modified Eagle medium 4.5 g/l glucose 
(DMEM, Life Technologies) supplemented with 5% FBS, 20 mg/ml vitamin B12 (Sigma) and 
100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). The collected cells were passed 
through a cell strainer (40 mm, BD Falcon) and then seeded onto four 100-mm plastic dishes 
for 2 hr at 37 °C in 5% CO2 and humidified atmosphere. The supernatant, composed mostly of 
CMs, was then collected, counted and plated at the appropriate density into BD Matrigel 
Matrix Growth Factor Reduced (356230 BD Bioscience) pre-coated Primaria 96-well plates 
(BD Falcon) or matrigel-coated Primaria 35-mm dishes (BD Falcon).  
 
METHOD DETAILS 
miRNA/siRNA transfection and EdU incorporation 
MicroRNAs and siRNAs (SMARTpool) were obtained from Dharmacon, Thermo Scientific 
and transfected into neonatal rat CMs using a standard reverse transfection protocol (Eulalio 
et al., 2012). Briefly, a transfection reagent (Lipofectamine RNAiMAX, Life Technologies) 
was diluted in OPTI-MEM (Life Technologies) and added to the miRNAs, siRNAs or a 
combination of the two (at a final concentration of 25 nM each nucleic acid), arrayed on 96-
well plates; 30 min later, 1x104 cells were seeded per well. Twenty-four hr after transfection, 
the culture medium was replaced by fresh medium; 28 h later, that is, 52 h after plating, the 
culture medium was replaced with medium containing 5 mM 5- ethynyl-29-deoxyuridine 
(EdU, Life Technologies) for 20 h. Cells were fixed at 72 h after plating and processed for 
immunofluorescence. Experiments were performed in quadruplicate.   
Immunofluorescence 
CMs were fixed with 4% PFA for 10 min, permeabilized with 0.5% Triton X-100 in PBS for 
10 min, followed by 1 hr blocking in 2% BSA (Roche). CMs were then stained overnight at 
4 °C with mouse monoclonal antibody against sarcomeric α-actinin (Abcam) diluted in 
blocking solution. Cells were washed with PBS and incubated for 2 hr with the secondary 
antibody conjugated to Alexa Fluor-488 (Life Technologies). Cells were further processed 
using the Click-IT EdU 555 Imaging kit (Life Technologies) to reveal EdU incorporation, 
according to the manufacturer’s instructions, and stained with Hoechst 33342. 
TEAD reporter assay 
For luciferase assays, CMs were plated at the concentration of 1.5x105 (day 0) in a double-
matrigel coated 96-Multiwell plate and, the subsequent day, were transfected with the selected 
miRNAs (Dharmacon). At day 2, the culture medium was replaced. At day 3, cells were 
transfected with 100 ng of both synthetic TEAD reporter firefly luciferase plasmid 
(p8xGTIIC-Lux, Plasmid #34615, Addgene) and a Renilla luciferase plasmid in OPTI-MEM 
(Life Technologies). After 4 hr, the medium was replaced with DMEM, Life Technologies, 
supplemented with 5% FBS, 20 mg/ml vitamin B12 (Sigma) and with 100 U/ml of penicillin 
and 100 mg/ml of streptomycin (Sigma). After 24 hr, firefly and fenilla luciferase activities 
were measured using the Dual Luciferase Reporter Assay System (Promega), according to the 
manufacturer’s instructions. 
Luciferase 3′-UTR reporter assays 
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Constructs bearing the rat 3′-UTR of Cofilin2, TAOK1 and β-TrCP were obtained by gene 
synthesis from Biomatik (3’UTR-Cfl2), Genewiz (3’UTR- β-TrCP and 3’UTR-TAOK1) or 
Integrated DNA Technology (3’ UTR-STK38L; gBlocks DNA synthesis) and subcloned into 
psiCHECK2.1 vector (Promega). HeLa cells were transfected with the miRNA under 
investigation at a final concentration of 50 nM in 96-well plates, through a standard reverse 
transfection protocol similar to that described above. Twenty-four hr later, cells were 
transfected with 100 ng per well of the reporter constructs or psiCHECK2 vector (control) 
using FuGENE HD transfection reagent (Promega). Firefly and Renilla luciferase activities 
were measured 48 hr after plasmid transfection using the Dual Luciferase Reporter Assay 
System (Promega), according to the manufacturer’s instructions. The mutated 3’-UTR of -
TrC and TAOK1 were obtained by using QuikChange II XL Site-Directed Mutagenesis Kit 
according to the manufacturer’s instructions using overlapping primers bearing the mutated 
sequences reported in Figure S3. The mutated 3’-UTR of Cofilin2 was obtained by gene 
synthesis (gBlocks) from Integrated DNA Technology. In all cases, the mutated sequences 
were cloned into the psiCHECK2.1 vector. The DNA sequence of all constructs was verified 
by Sanger sequencing.  
Nuclear/cytoplasmic fractionation 
Cells (1x106 cells were plated in matrigel-coated Primaria 60-mm dishes (BD Falcon) as 
described above. miRNAs were transfected by a standard forward transfection protocol. 
Seventy-two hr after transfection, cells were washed with ice-cold PBS and harvested in 80 µl 
of hypotonic buffer (50 mM Tris pH7.5, 10 mM NaCl, 3 mM MgCl2, 10% glycerol) 
supplemented with protease inhibitors (complete tablets, Mini EDTA-free, Roche) and 
phosphatase inhibitors (cocktail 3 Sigma, 2mM orthovanadate, 1 mM NaF). After 1 min, cells 
were scraped and NP40 was added at 0.1% final concentration. After 5 min on ice, cells were 
centrifuged at 4000 rpm for 5 min at 4 ºC; the supernatant and cytosolic fractions were then 
recovered. Pellets were resuspended in 70 µl IPLS buffer (50 mM Tris pH 7.5, 120 mM NaCl, 
1 mM EDTA, 0.5% NP40, supplemented with the same inhibitors as above) and sonicated 
with 3 pulses of 10 min each (30 sec on/30sec off) on ice in a Bioruptor™ Plus (Biosense). 
Nuclear lysates were centrifuged at 16,000 rpm for 20 min at 4 ºC and the supernatant was 
recovered as nuclear fraction. Concentration of cytoplasmic and nuclear lysates were 
measured using the Bradford assay (Protein Assay Dye Reagent Concentrate, Bio Rad). 
Lysates (10 to 20 µg) were loaded for protein separation and subsequent blotting onto a PVDF 
membrane (Amersham™ Hybond™ PVDF, GE Healthcare). 
Cardiomyocyte treatments 
Cytochalasin D (sc_201442, Santa Cruz) was added to the CM culture medium at the final 
concentration of 0.1 µM for 2-6 hr;  Jasplakinolide (J4580, Sigma-Aldrich) at 0.5 μM for 30-
90 min; FGF1 at 50 ng/mL, readministered every 24 hr for 72 hr; the p38 inhibitor SB203580 
at 40 μM for 72 hr; phenylephrine at 50 μM for 24 hr. 
G/F actin separation and immunoblotting 
The amount of G-actin and F-actin in CMs was quantified using G-actin/F-actin in vivo assay 
kit (Cytoskeleton Inc.) according to the manufacturer's instructions. Briefly, cells were lysed 
in pre-warmed lysis/F-actin stabilizing buffer supplemented with protease inhibitor and ATP. 
The cell lysate was centrifuged for 5 min at 350×g to remove debris. A 100 µl aliquot was 
then ultracentrifuged at 100,000×g for 1 hr at 37 °C to pellet F-actin, with G-actin remaining 
in the supernatant. The pellet was resuspended in 100 µl of F-actin destabilizing buffer on ice 
for 1 hr with frequent pipetting. Equal volumes of G-actin and F-actin fractions were mixed 
with 5×SDS sample buffer and run on SDS-PAGE. Western blot analysis was performed using 
the anti -actin antibody provided in the kit. Densitometry analysis was performed using the 
ImageJ software. 
ATPlite™ luminescence assay 
ATPlite™ Luminescence Assay System (PerkinElmer) was performed according to the 
manufacturer’s protocol. Briefly, 50 μl of mammalian cell lysis solution were added to 100 μl 
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CM suspension per well and plates were shaken at 700 rpm for 5 min. Next, 50 μl substrate 
solution were added to each well, followed by a second round of shaking (5 min at 700 rpm). 
Luminescence was the measured using a Wallac EnVisionTM 2104 MultiLabel Reader. 
RNA isolation and quantitative real-time PCR 
Total mRNA was isolated from CMs 72 hr after transfection, or at different time points after 
cytochalasin D treatment, using a standard TRIZOL RNA isolation protocol. The RNA 
obtained (1 μg) was reverse-transcribed using MLV-RT (Invitrogen) with random hexamers 
(10 μM) in a 20 μl reaction, following the manufacturer’s instructions. mRNA levels for 
CTGF, CyR61 and GAPDH were measured by Real-Time PCR using pre-designed TaqMan 
assays (Thermofisher) and iQ™Supermix (Bio-Rad) according to the manufacturer’s 
instruction. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical analysis 
Unless otherwise indicated, all data are expressed as mean ± standard error of the mean 
(SEM). One-way ANOVA followed by post-hoc analysis with the Bonferroni’s Multiple 
Comparison Test was used for the analysis of multiple groups; two-tail Student’s t-test was 
used to compare two individual groups. GraphPad Prism version 6 was used for statistical 
analyzes included in the main and supplementary figures of the study. 
Bioinformatics 
Transcriptomic analysis. Deep-sequencing of total neonatal rat CM RNA was performed 72 
hr after transfection of the microRNAs by IGA Technology Services, Udine, Italy as in ref. 
(Eulalio et al., 2012). Briefly, RNA purity, integrity and concentration were determined using 
an Agilent 2100 Bioanalyzer (Agilent Technologies). Only RNA with a RIN value >7 and an 
rRNA 28S/18S ratio >2 was taken forward for sample preparation. Two μg of total RNA 
(minimum concentration of 200 ng/μl) per sample were sequenced on an Illumina HiSeq2000. 
Two lanes in 7-plex were run obtaining 20 million single-reads per sample, 50-bp long. The 
raw sequencing data discussed in this publication have been deposited in NCBI's Sequence 
Read Archive (SRA) and are accessible through SRA STUDY accession SUB2866022. 
Real-time image analysis, base calling, de-multiplexing and production of FASTQ sequence 
files were performed on the HiSeq2000 instrument using the HiSeq Software. Raw sequence 
files were quality checked using FASTQC software 
(www.bioinformatics.babraham.ac.uk/projects/fastqc) and trimmed to remove Illumina 
adaptor using Cutadapt software (Martin, 2011). RNA-seq reads were mapped to Rattus 
norvegicus reference genome (GCF_000001895.5  Rnor 6.0.82) and to known mature 
miRNAs using STAR software (Dobin et al., 2013). Rounded Gene counts were used as input 
and transformed to RPKM (reads per kilobase of exon model per million mapped reads) using 
Bioconductor package edgeR rpkm function (McCarthy et al., 2012).  
In the case of transfection of a pro-proliferative miRNA, genes whose RPKM values were 
greater than 1.00 in both miRNA and cel-miR-67 control-transfected rat CMs were 
considered as expressed. Fold changes were taken with respect to the expression of cel-miR-
67 control. Genes whose fold changes were greater than 1.3 (both upregulated and 
downregulated) were considered as differentially expressed. 
Clustering of fold change expression levels. Cluster analysis was performed on the basis of 
the log2-fold changes in gene expression in respect to cel-miR-67 to classify the pro-
proliferating miRNAs according to their effects on CMs upon transfection. In brief, the 
correlation between the log2-fold changes for all pairs of miRNAs were calculated. Clusters 
were then identified hierarchically using the average linkage criterion with a Euclidean 
distance metric as implemented in the clustering package of SciPy v0.18.1 
(http://www.scipy.org). Dendrograms were then generated to visualize the arrangement of the 
resulting cluster. 
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Bioinformatic target prediction. To the best of our knowledge, bioinformatic predictions of 
seed sequence interactions with rat transcripts are not available. Because of this constraint, we 
compiled a list of rat miRNA-gene interactions from mouse predictions. In particular, 
predicted mouse gene targets of the seed sequences (corresponding to miRNA families) of 
pro-proliferative miRNAs were collected from TargetScanMouse Release 7.1 (Agarwal et al., 
2015). The mouse genes were then converted to their corresponding rat genes via homology 
using the HomoloGene database (Coordinators, 2017). The list of miRNA-gene interactions 
was filtered to only include genes that were downregulated by the miRNA upon transfection 
to CMs according to the transcriptomic data. 
 
DATA AND SOFTWARE AVAILABILITY 
RNA-seq data have been deposited at GEO under accession GSE129598. 
. 
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Figure S1. Related to Figure 1. Summary of miRNA sequences used in this study. Sequence, 
miRBase accession number and chromosomal location of the human miRNAs included in the study. 
Sequences of the corresponding miRNAs in mouse, rat and pig available in the miRBase 21 database 
(http://www.mirbase.org) are also reported. The seed sequence is in red. 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Figure S2. Related to Figure 2.  Expression profiles of NCBI genes in pro-proliferative miRNA-
treated neonatal CMs. A. Schematic representation of RNAseq experiments. Neonatal rat CMs were 
reverse transfected with the indicated miRNAs, followed by RNA sequence analysis using Next 
Generation Sequencing (NGS). Total neonatal rat CM RNAs were deep-sequenced and quantified using 
standard protocols. The gene expressions mapped onto the Rattus norvegicus reference genome 
(GCF_000001895.5 Rnor 6.0.82) was then normalized by RPKM. Expressed genes are those for which 
the expression is above 1.00 RPKM. Fold-changes in gene expression upon transfection of pro-
proliferating miRNA were taken with respect to cel-miR-67 (negative control). B. Heatmap of gene 
expression profiles; downregulated genes are shown in green, upregulated genes in red. Cluster analysis 
was performed on the log2-fold-change over control (cel-miR-67). The dendrogram shows the 
arrangement upon hierarchical clustering using an average linkage criterion with a Euclidean distance as a 
metric. MiR-302d and miR-373 have very similar effects compared to the other miRNAs considered in 
this study. The plot also indicates that miR-199a-3p had an effect which is least similar to the other 5 
analyzed miRNAs. C. Heatmaps showing differentially expressed genes in response to the 6 miRNAs. 
Green identifies downregulated (total 96 genes) and red upregulated genes (156 genes). D. Common 
regulatory pathways mediate activity of miRNAs inducing CM proliferation. Pathway analysis revealed 
alterations in the levels of genes involved in the Hippo and the F-acting polymerization pathways. 
Upregulated genes are in red, downregulated genes in green. Fold changes are in brackets. 
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Figure S3. Related to Figure 2.  Effect of the 10 pro-proliferative miRNAs on the 3' UTRs of 
selected target genes. Rsults of 3'UTR luciferase assays. The Renilla luciferase (Rluc) values were 
normalized over the firefly luciferase (Fluc) values and are expressed as folds over the effect of C. 
elegans miR-67 in Control. Control refers to transfection of a Renilla luciferase gene with no 3'UTR. In 
all the experiments, data are mean±SEM of at least n=3 independent experiments; *P<0.05; one-way 
ANOVA. A. Effects of miRNAs on the TAOK1 3'UTR. B. Predicted pairing of miR-199a-3p onto the 
TAOK1 3'UTR (miRNA seed sequence is in red) and sequence of a 3'UTR mutated in the miRNA-pairing 
sequence mutated nucleotides are in green). Nucleotide numbers refer to the NCBI Reference Sequence 
NM_173327.1 for rat TAOK1. C. 3'UTR luciferase assays with the mutated TAOK1 3'UTR sequence in 
cells transfected with miR-199a-3p or miR-590-3p (as a control). D. Effects of miRNAs on the β−TrCP 
3'UTR.  E. Predicted pairing of miR-199a-3p onto the β−TrCP 3'UTR and sequence of a 3'UTR mutated 
in the miRNA-pairing sequence. Nucleotide numbers refer to the NCBI Reference Sequence 
NM_001007148.2 for rat β−TrCP. F. 3'UTR luciferase assays with the mutated β−TrCP 3'UTR sequence 
in cells transfected with miR-199a-3p or miR-590-3p. G. Effect of miRNAs on theSTK38L 3'UTR.  H. 
Predicted pairing of miR-199a-3p onto the Cofilin2 3'UTR (miRNA seed sequence is in red) and 
sequence of a 3'UTR mutated in the miRNA-pairing sequence (mutated nucleotides are in green). 
Nucleotide numbers refer to the NCBI Reference Sequence NM_001108982.2 for rat Cofilin2. I. 3'UTR 
luciferase assays with the mutated Cofilin2 3'UTR sequence in cells transfected with miR-199a-3p or 
miR-590-3p (as a control). Data are mean±SEM of n=3 independent experiments.  
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Figure S4. Related to Figure 2.  Downregulation of YAP blunts the pro-proliferative activity of 
siRNAs against TAOK1 and β−TrCP. Representative images of CMs treated with the indicated siRNAs 
with or without a siRNA against YAP. Scale bar: 100 µm. 
.  
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Figure S5. Related to Figure 6.  Effect of the actin cytoskeleton stabilizing drug jasplakinolide on 
YAP nuclear levels. A. Time-dependent cell cytotoxicity after neonatal rat CM treatment with 
jasplakinolide (JAsp). B and C. Levels of nuclear YAP1 after CM treatment with jasplakinolide for the 
indicated time points (representative western blot and quantification, respectively. Data are mean±SEM of 
n=3 independent experiments; *P<0.05 one-way ANOVA. 
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Figure S6. Related to Figure 6. Requirement of YAP for cardiomyocyte proliferation upon 
treatment with different stimuli. A and B. Representative western blotting (A) and quantification (B) of 
the levels of nuclear YAP upon treatment of neonatal rat CMs with the indicated treatments (transfection 
with mi-R199a-3p; treatment with FGF1 in combination with an inhibitor of p38 and treatment with the 
pro-hypertrophic stimulus phenylephrine). Transfection of the irrelevant hsa-miR-665 served as negative 
control. The levels of nuclear PARP1 are a loading control. Data are mean±SEM of n=3 independent 
experiments. C. TEAD reporter transcription assays in CMs exposed to the same stimuli as in panels A 
and B. Transfection of a plasmid expressing the constitutively active pYAP55A mutant served as positive 
control. Data are mean±SEM of n=3 independent experiments; **P<0.01, *P<0.05 one-way ANOVA. D. 
EdU incorporation in neonatal rat CMs treated with the same stimuli as in the other panels with or 
without treatment with an siRNA against YAP. The graph shows the percentage of sarcomeric α-actinin-
positive cells (cardiomyocytes) that have incorporated EdU in a 72 hr period. Data are mean±SEM (n=3 
independent experiments); * **P< 0.01; one-way ANOVA. 
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Table S1. Related to Figure 2. Effect of pro-proliferative miRNAs on a catalogue of genes involved 
in the Hippo pathway. An extensive literature search was performed to compile a list of rat genes that 
were experimentally found to modulate YAP-mediated gene activation. The canonical and non-canonical 
Hippo pathway genes are listed along with upstream interactors and downstream effectors. For each 
catalogued gene, the log2-fold change of gene expression level in cardiomyocytes treated with each of the 
analyzed miRNAs (hsa-miR-1825, hsa-miR-199a-3p, hsa-miR-302d-3p, hsa-miR-33b-3p, hsa-
miR-373-3p and hsa-miR-590-3p) compared to cel-miR-67 is reported. If differentially expressed, the 
reported log2-fold change is indicated as either upregulated (in red) or downregulated (in green). 
Bioinformatic predictions between the miRNA and the gene is also reported where an indication whether 
a strong interaction (shown in yellow) was predicted. 
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Table S2. Related to Figure 3. Effect of pro-proliferative miRNAs on a catalogue of genes involved 
in actin microfilament assembly and disassembly. Same as Table S1 using a list of genes reported in 
the literature that experimentally regulate the assembly and disassembly of actin microfilaments. 
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